Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H39FN4O4.ClH.H2O |
| Molecular Weight | 593.13 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@H](CC3=CC=C(F)C=C3)C(=O)NCCCC4=CC=CC=C4O1
InChI
InChIKey=ZWIXEQBDJMFCMN-DHHNQDMHSA-N
InChI=1S/C30H39FN4O4.ClH.H2O/c1-19-18-33-27(23-12-13-23)30(38)35(3)20(2)28(36)34-25(17-21-10-14-24(31)15-11-21)29(37)32-16-6-8-22-7-4-5-9-26(22)39-19;;/h4-5,7,9-11,14-15,19-20,23,25,27,33H,6,8,12-13,16-18H2,1-3H3,(H,32,37)(H,34,36);1H;1H2/t19-,20-,25-,27+;;/m1../s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C30H39FN4O4 |
| Molecular Weight | 538.6535 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ulimorelin (TZP101) is a small molecule, intravenously administered, ghrelin receptor agonist that is being developed by Lyric Pharmaceuticals. Ulimorelin stimulates intestinal motility, but also reduces blood pressure in rodents and humans and dilates blood vessels. It has been proposed as a treatment for intestinal motility disorders. Ulimorelin has progressed to phase III human clinical trials for the treatment of postoperative ileus.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. | 2015-04-05 |
|
| The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. | 2014-02 |
|
| Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic. | 2011-12-22 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23739196
Partial bowel resection: Thirty-minute intravenous infusions (160 ug/kg, 480 ug/kg ulimorelin, or placebo) once daily were started within 60 minutes after the end of surgery and ended at the first of the following: primary efficacy end point fulfilled (defined below), hospital discharge, or 7 days treatment.
Route of Administration:
Intravenous
Ulimorelin (0.03-30uM) inhibited phenylephrine-induced contractions of rat saphenous (IC50=0.6uM; Imax=66±5%; n=3-6) and mesenteric arteries (IC50=5uM, Imax=113±16%; n=3-4). In mesenteric arteries, ulimorelin, 1-10uM, caused a surmountable rightward shift in the response to phenylephrine (0.01-1000uM; pA2=5.7; n=3-4). Ulimorelin is an agonist of G-protein coupled receptor (Ki=16 nM, EC50=29 nM).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:15:55 GMT 2025
by
admin
on
Mon Mar 31 19:15:55 GMT 2025
|
| Record UNII |
662MCS79XH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C78276
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
WW-61
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
951326-02-6
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
DTXSID70241766
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
SUB121120
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
56841653
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
C102755
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
m11299
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
DBSALT002140
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
300000048017
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL1963249
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY | |||
|
662MCS79XH
Created by
admin on Mon Mar 31 19:15:55 GMT 2025 , Edited by admin on Mon Mar 31 19:15:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |